What Enelbin Treats: Main Uses and Benefits

Enelbin (Naftidrofuryl oxalate) is commonly used to provide symptomatic support across clinical domains where symptoms are driven by impaired blood flow and insufficient tissue circulation. Its application is focused on offering relief that helps patients cope more steadily with chronic or recurrent manifestations of vascular disease, and may be part of symptomatic management to support function and ease discomfort. It is considered relevant for the management of these conditions.

---

Easing Pain and Improving Function in Peripheral Arterial Disease

This medication is commonly used to manage the distressing symptoms of Intermittent Claudication, characterized by cramping, fatigue, and pain in the legs that arise during walking due to restricted circulation. The therapeutic goal commonly involves assisting with an increase in the pain-free walking distance, which generally supports patient mobility and contributes to improved comfort despite the chronic condition.

The medication is relevant for a range of conditions involving circulatory compromise, including the management of Peripheral Arterial Disease, ischemic rest pain, night cramps, and supportive therapy for chronic ulcers.

Quick Fact: Relief for Intermittent Claudication The use is aligned with the goal of assisting patients with Peripheral Arterial Disease to help improve their pain-free walking distance.

---

Relief for Severe Ischemic Discomfort and Chronic Cerebrovascular Symptoms

Enelbin is applied in clinical settings involving more severe circulatory issues to help manage ischemic rest pain and disruptive night cramps, where discomfort is present even without exertion. It offers supportive therapeutic benefit that is relevant for tissue support, which is useful for the management of trophic lesions and chronic ulcers and is applied in the management of these conditions. It is also considered relevant in clinical contexts where symptoms like concentration difficulties or functional decline are associated with chronic reduced blood flow to the brain, supporting day-to-day mental activities.

Regulatory References

1. National Institute for Health and Care Excellence (NICE)

Who Can and Cannot Use Enelbin (Naftidrofuryl Oxalate)

Eligibility for using Enelbin is strictly defined by regulatory authorities based on specific patient populations and pre-existing medical conditions.

---

Absolute Contraindications

Enelbin must not be used by individuals who fall into the following categories, as they represent absolute contraindications:

• Patients with known hypersensitivity to naftidrofuryl oxalate or its excipients.
• Individuals with a history of hyperoxaluria or recurrent calcium-containing kidney stones.
• Patients diagnosed with Atrioventricular (AV) block.

Population and Conditional Restrictions

Population Group	Regulatory Eligibility Status
Children (Pediatric)	Not indicated for use in this age group.
Pregnancy	Not advisable due to the absence of relevant clinical data.
Lactation	Should not be used by breast-feeding women.
Renal/Hepatic Impairment	Requires caution for patients with insufficiency.
Severe Cardiac Conditions	Requires caution for patients with severe cardiac insufficiency or other conduction disorders (excluding AV block).

Use of Enelbin is established primarily for the adult and older adult population, provided none of the above contraindications or restrictions apply.

Interactions with other medicines and products

Enelbin is a brand name for the active ingredient Naftidrofuryl, a peripheral vasodilator. The regulatory status of Naftidrofuryl as a drug for well-established use, particularly in Europe, informs its interaction profile.

---

Official Interaction Profile for Naftidrofuryl (Enelbin)

Naftidrofuryl is generally considered to have a low risk of clinically significant systemic drug-drug interactions when used as prescribed. This low risk is primarily based on the drug's established metabolic pathway and its minimal effect on major drug-metabolizing enzymes.

Product Class/Category	Interaction Classification	Statement from Regulatory Labeling
Anticoagulants	Caution	No specific or significant interactions are documented. Monitoring of anticoagulant effect is generally recommended for any concurrent therapy.
Cytochrome P450 Substrates/Inhibitors	Unlikely/Not Significant	Naftidrofuryl is not known to be a potent inhibitor or inducer of the major Cytochrome P450 (CYP) enzyme systems (e.g., CYP3A4, CYP2D6), which minimizes the potential for pharmacokinetic interactions with most other medicines.
Food/Beverages	Not Established	No definitive interaction with food or non-medicinal products is officially documented.

---

Due to the negligible systemic exposure and primary elimination pathway of Naftidrofuryl, the potential for drug interactions is considered minimal. Regulatory documents do not list any specific, absolute contraindications related to drug-drug interactions. Patients should still inform their healthcare provider of all concomitant medicinal products, including prescription drugs and over-the-counter treatments, to ensure comprehensive safety monitoring.

Enelbin is a fixed-dose combination preparation containing the proteolytic enzymes trypsin and bromelain, and the bioflavonoid rutoside (also known as rutin). Following oral administration, the components are absorbed systemically. The mechanism of action involves the simultaneous modulation of multiple pathways.

Rutoside primarily functions as an antioxidant and capillary stabilizer. It modulates intracellular signaling by inhibiting intracellular calcium mobilization in platelets, thereby acting as an inhibitor of platelet aggregation. At the cellular level, it suppresses the phosphorylation and activation of Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), which prevents the activation of the transcription factor Activator Protein 1 (AP-1), and also decreases the activation of Nuclear Factor-kappa B (NF-kappaB). The downstream cascade involves the inhibition of pro-inflammatory cytokine gene transcription in macrophages, including Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6).

Trypsin acts as a serine protease that mediates fibrinolysis by displacing bound plasmin from plasma proteins. It also reduces the release of inflammatory mediators and cleaves molecules on antigen-presenting cells, increasing the activation threshold of T cells. Bromelain, a cysteine protease, reduces vascular permeability by depleting kininogen, which is required for producing bradykinin. Both proteases modulate adhesion molecules, inhibit leukocyte migration, and promote macrophage differentiation toward a tissue-repair profile (M2).

Official Administration Guidelines for Enelbin (Naftidrofuryl Oxalate)

These instructions outline the proper administration of Enelbin according to clinical guidelines. Strict adherence to the documented regimen and administration procedure is required for safe use.

Dosing and Frequency

Category	Official Instruction
Route of Administration	Oral (Capsules/Tablets)
Standard Daily Dose	mathbf300,mg to mathbf600,mg total daily
Frequency	Three times daily (t.i.d.)
Duration	For specific chronic conditions, treatment is typically initiated for a minimum of three months or as determined by a physician.

Administration Procedure and Special Conditions

To ensure proper use and mitigate local risks, every dose must be administered according to specific procedural steps:

1. Swallow the Capsule Whole: The capsule must be swallowed intact; do not chew, crush, or open the capsule.
2. Take with Meals: Each dose should be consumed with or immediately after food.
3. Mandatory Fluid Intake: It is essential to swallow the capsule with a sufficient amount of water (e.g., at least one full glass). This is a critical instruction to prevent the capsule from lodging in the esophagus, which may cause local irritation, and to help maintain adequate diuresis to prevent calcium oxalate stone formation.

Population-Specific Use

The safety and efficacy of Naftidrofuryl in the pediatric population (children and adolescents) have not been established, and the drug is not indicated for use in this age group. Dose adjustments or special caution may be required for patients with renal or hepatic impairment.

Missed Dose Rule: If a dose is forgotten, the patient should take the next scheduled dose at the regular time. Do not take a double dose to compensate for the missed one.

Research evidence / Overview of studies for Enelbin

This section describes the types of clinical studies that have been conducted to evaluate Naftidrofuryl oxalate, the specific measures and outcomes examined by researchers, and the current limitations of the evidence, as reported by authoritative regulatory and scientific sources.

---

Evidence for Symptomatic Intermittent Claudication

The primary body of research for Enelbin was evaluated in the context of symptomatic Intermittent Claudication (IC). This condition is associated with functional limitations due to poor blood flow in the legs, often resulting in pain during walking.

The evidence base consists primarily of Randomized Controlled Trials (RCTs), with findings aggregated in systematic reviews and meta-analyses. These studies explored adult patients with IC whose symptoms persisted after initial conventional management. The research focused on outcomes related to physical discomfort, specifically monitoring changes in the distance patients could walk, such as the Pain-Free Walking Distance and Maximal Walking Distance. The aggregated data show patterns related to these functional measurements.

---

Research Landscape for Chronic Cerebrovascular Symptoms

Enelbin was also studied for use in conditions linked to chronic reduced blood flow to the brain, such as symptoms related to chronic cerebral ischemia. The research in this area was evaluated in a body of older clinical trials and separate systematic literature reviews. These studies explored cohorts experiencing symptoms linked to poor circulation, monitoring patient status related to cognitive performance, mood, behavior, and rehabilitation protocols. However, the findings in this area were observed in some studies, and consistency remains low. Evidence quality varies across studies, and there is limited information from recent, large-scale RCTs for these specific indications.

---

Evidence Gaps and Areas of Research Uncertainty

Long-term effects are not fully established because follow-up durations were limited in many of the key trials (typically 3-6 months). The research does not currently provide extensive data regarding observations when the medicine is taken continuously over many years.

The research was not designed or powered to assess whether Naftidrofuryl oxalate impacts major clinical events over a patient's lifetime. There is limited information for long-term outcomes regarding potential effects on cardiovascular events or mortality. Data for certain groups remain insufficient, and sample sizes were small in some trials, meaning the results apply only to the specific populations studied.

Key Studies & References

1. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication in people with peripheral arterial disease (NICE Technology Appraisal Guidance 223)
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index

Common questions about Enelbin (FAQ)

---

Q: Can Enelbin be taken on an empty stomach?

According to the official product information and administration guidelines, the capsule should be swallowed with or immediately after food. The official instructions also emphasize taking it with a sufficient amount of water. These steps are specified to help prevent local irritation and reduce the risk of kidney stone formation.

---

Q: Is it safe to drink a little alcohol while using Enelbin?

Regulatory documents state that there is no definitive interaction documented between Enelbin and non-medicinal products, which includes alcohol. However, regulatory bodies note the importance of consulting a healthcare provider regarding all concomitant substances, including alcohol, when starting a new medicine.

---

Q: Is it normal to feel a difference right away after starting Enelbin? / How quickly should I expect Enelbin to start working?

Official information indicates that treatment duration is long-term. Clinical data shows that treatment is typically initiated for a minimum of three months before assessing its full effect. Therefore, clinical practice indicates effects are evaluated over a period of time, rather than immediately.

---

Q: How long does a course of Enelbin treatment usually last?

For the specific chronic conditions this medicine addresses, treatment is typically initiated for a minimum of three months. Decisions about extending therapy beyond this initial period are made by a qualified healthcare professional.

---

Q: Does Enelbin have any reported interactions with common cold medicines?

Official interaction profiles report a low risk of clinically significant drug-drug interactions with Enelbin. This is primarily because the medicine is not known to be a strong modulator of the major drug-metabolizing enzyme systems. Patients are instructed in official labeling to inform their healthcare provider of all medicines being taken, including over-the-counter cold remedies.

---

Q: Are there any food or drinks to avoid while taking Enelbin?

Regulatory labeling states there is no definitive interaction with food or non-medicinal products officially documented. Nonetheless, the capsule should always be taken with food and water as part of the administration instructions.

---

Q: Can older adults safely use Enelbin, according to official information?

Use of Enelbin is established primarily for the adult and older adult population. The established use is subject to the absence of specific contraindications (conditions that forbid its use) or restrictions listed in the official documents.

---

Q: What kind of research has been done on Enelbin's long-term effects?

The research primarily consists of trials with limited follow-up durations, typically lasting between three to six months. Regulatory sources indicate that long-term effects are not fully established, and there is limited data regarding observations when the medicine is taken continuously over many years.

---

Q: Is Enelbin known to cause dizziness or affect driving?

The official side effect profile does not list dizziness or vertigo as a common adverse reaction. However, regulatory documents caution that high doses or overdose may potentially affect the Central Nervous System (CNS), leading to serious effects such as convulsions.

---

Q: What is Enelbin used for, besides the main thing? / Why is Enelbin sometimes given to people who don't have the condition it's mainly for?

The main body of research focuses on Intermittent Claudication (impaired blood flow in the legs). However, studies have also evaluated its use for other conditions related to chronic reduced blood flow to the brain, specifically symptoms linked to chronic cerebral ischemia.

---

Q: Is Enelbin an anti-inflammatory or a pain reliever?

According to its official classification, Enelbin is designated as a Peripheral Vasodilator and a vasoactive agent. Its primary mechanism of action is to influence the tone of blood vessels to improve blood flow in the circulatory system.

---

Q: Do you need a prescription to get Enelbin in most places?

Yes, regulatory authorities designate Enelbin as a prescription-only medicine. This means that it can only be legally supplied to an individual with a valid prescription from a licensed healthcare professional.

---

Q: Is Enelbin safe to take if I have high blood pressure?

The medicine is not specifically contraindicated for high blood pressure alone. However, caution is required for patients with severe cardiac conditions and other conduction disorders. Naftidrofuryl may have mild effects on blood pressure, and the importance of monitoring by a healthcare professional is noted in the regulatory documents.

---

Q: Does Enelbin have a risk of dependence or addiction?

The active ingredient, Naftidrofuryl oxalate, is not classified as a controlled substance by regulatory authorities. This classification indicates the medicine is not considered to have a recognized risk of dependence or addiction based on available labeling information.

---

Q: What body systems does Enelbin primarily affect?

Enelbin is a peripheral vasodilator whose primary action is to influence the blood flow in the circulatory system. This effect specifically targets the peripheral vascular system (limbs) and has also been studied in relation to the cerebral vascular system (brain).

---

Q: Is Enelbin suitable for people with diabetes?

Regulatory information includes the use of Enelbin for peripheral vascular disorders, such as poor circulation caused by diabetes, specifically known as diabetic arteriopathy. The medicine is used under the guidance of a healthcare provider.

---

Q: Are there any specific safety warnings for women taking Enelbin?

Yes. Specific restrictions are detailed for women who are pregnant or breast-feeding due to the absence of sufficient clinical data in these populations. The full official safety information should be reviewed for conditions related to pregnancy and breastfeeding.

---

Q: Are there any long-term safety concerns noted for Enelbin use?

Official safety labeling highlights the rare, but clinically significant, adverse reactions of liver damage and the formation of calcium oxalate kidney stones. These are the primary serious long-term concerns identified in regulatory documents.

---

Q: Are there any known interactions between Enelbin and herbal remedies?

While the overall risk for systemic drug-drug interactions is noted as low, official patient information notes the importance of informing the healthcare provider of all concomitant medicinal products. This includes prescription drugs, over-the-counter treatments, and all herbal and complementary medicines.

---

Q: Are there specific symptoms that signal a rare, serious side effect of Enelbin?

The most serious rare side effect highlighted is liver damage. Official guidelines state that in the event of signs or symptoms suggesting liver issues, such as yellowing of the skin and eyes (jaundice), the medicine must be discontinued and the patient should seek professional medical evaluation.

---

Q: Can men and women use Enelbin interchangeably, according to research?

The medicine is indicated for use across the adult population. Restrictions and specific cautions are detailed only for pregnant or breast-feeding women. No other sex-based differences in general use or dosing for the general adult population are noted in regulatory labeling.

How to Store and Dispose of Enelbin (Naftidrofuryl Oxalate)

The storage and disposal of Enelbin tablets must strictly comply with the requirements defined in the official regulatory labeling.

---

Storage Conditions

Item	Requirement
Temperature	Store at room temperature and below 30 C.
Protection	Keep in the original container to protect from moisture and light.
Handling	The product must be stored out of the sight and reach of children.
Stability	Do not use the medicine after the expiry date (EXP) on the packaging.

---

Disposal Instructions

Unused or expired Enelbin must be disposed of according to local regulatory requirements for pharmaceutical waste. Do not discard the medicine by flushing it down the toilet or pouring it into a drain (wastewater), and do not place it in ordinary household trash.